Market research
NUVB Nuvation Bio Inc
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 13.1
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US67080N1019
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 13.1
- Dividend yield
- Not available
- Beta
- 1.53
About
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the NUVB discussion.
No comments yet
Start a focused discussion about NUVB.